Subjects | 303 |
Age at nivolumab initiation years | 65 (17–91) |
Sex | |
Male | 208 (69) |
Female | 95 (31) |
Smoking history | |
Never-smoker | 23 (8) |
Current or ex-smoker | 278 (92) |
Missing data | 2 (1) |
Histology on initial biopsy | |
Adenocarcinoma | 186 (61) |
Squamous cell carcinoma | 86 (28) |
Giant cell carcinoma | 20 (7) |
Sarcomatoid carcinoma | 4 (1) |
Adenosquamous carcinoma | 3 (1) |
Muco-epidermoid carcinoma | 2 (1) |
Undifferentiated EBV-linked carcinoma | 1 (<1) |
Missing | 1 (<1) |
Mutational status | |
EGFR | 10 (3) |
KRAS | 50 (17) |
ALK | 2 (1) |
BRAF | 7 (2) |
Wild-type | 219 (72) |
Other | 15 (5) |
Stage at diagnosis | |
Stage I–II | 30 (10) |
Post-operative recurrence | 26 (87) |
Stage III–IV | 273 (90) |
Lines of therapy before nivolumab | 2 (0–9) |
0 | 1 (<1) |
1 | 120 (40) |
2 | 88 (29) |
≥3 | 94 (31) |
Performance status at nivolumab initiation | |
0 | 59 (19) |
1 | 145 (48) |
2 | 60 (20) |
3 | 7 (2) |
4 | 2 (1) |
Missing | 30 (10) |
Metastatic sites at nivolumab initiation | |
Lung | 120 (40) |
Pleura | 88 (29) |
CNS | 62 (20) |
Liver | 48 (16) |
Adrenal glands | 54 (18) |
Bone | 78 (26) |
PD-L1 status determined by IHC | 120 (40) |
Positive (>1%) | 31 (10) |
Negative | 32 (11) |
Not performed | 240 (79) |